

# Gordon Cook

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1051363/gordon-cook-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

129  
papers

4,534  
citations

32  
h-index

66  
g-index

142  
ext. papers

5,736  
ext. citations

5.3  
avg, IF

4.98  
L-index

#	Paper	IF	Citations
129	Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2102228	2.2	5
128	Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results.. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 52	7	1
127	Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FITNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. <i>BMJ Open</i> , <b>2022</b> , 12, e056147	3	0
126	Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. <i>Haematologica</i> , <b>2021</b> , 106, 1957-1967	6.6	6
125	Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy. <i>British Journal of Haematology</i> , <b>2021</b> ,	4.5	4
124	Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial. <i>British Journal of Haematology</i> , <b>2021</b> ,	4.5	
123	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , <b>2021</b> , 8, e934-e946	14.6	9
122	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. <i>HemaSphere</i> , <b>2021</b> , 5, e528	0.3	19
121	Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. <i>Leukemia</i> , <b>2021</b> , 35, 2043-2053	10.7	10
120	Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial. <i>British Journal of Haematology</i> , <b>2021</b> , 193, e19-e22	4.5	1
119	Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 750-760	4.5	1
118	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , <b>2021</b> , 22, e105-e118	21.7	32
117	Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. <i>British Journal of Haematology</i> , <b>2021</b> , 194, 132-139	4.5	2
116	Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. <i>Annals of Hematology</i> , <b>2021</b> , 100, 2325-2337	3	4
115	Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients. <i>Haematologica</i> , <b>2021</b> , 106, 2754-2758	6.6	9
114	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. <i>Leukemia</i> , <b>2021</b> , 35, 18-30	10.7	29
113	Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. <i>British Journal of Haematology</i> , <b>2021</b> , 192, 853-868	4.5	5

112	Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. <i>Leukemia</i> , <b>2021</b> , 35, 1732-1744	10.7	3
111	Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. <i>PLoS Medicine</i> , <b>2021</b> , 18, e1003454	11.6	4
110	How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma. <i>Clinical Hematology International</i> , <b>2021</b> , 3, 27-33	1.8	
109	Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia. <i>Oncology and Therapy</i> , <b>2021</b> , 9, 139-151	2.7	0
108	COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myeloma. <i>British Journal of Haematology</i> , <b>2021</b> ,	4.5	4
107	Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 111	7	3
106	Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. <i>Blood</i> , <b>2020</b> , 136, 3033-3040	2.2	84
105	Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. <i>British Journal of Haematology</i> , <b>2020</b> , 190, e83-e86	4.5	60
104	Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network. <i>Leukemia</i> , <b>2020</b> , 34, 2285-2294	10.7	28
103	Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. <i>Leukemia</i> , <b>2020</b> , 34, 3091-3096	10.7	13
102	Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. <i>Blood</i> , <b>2020</b> , 136, 1091-1104	2.2	23
101	Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. <i>Haematologica</i> , <b>2020</b> , Online ahead of print,	6.6	4
100	Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. <i>Leukemia</i> , <b>2020</b> , 34, 1875-1884	10.7	77
99	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , <b>2020</b> , 34, 2000-2011	10.7	71
98	The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor. <i>Trials</i> , <b>2020</b> , 21, 826	2.8	2
97	An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 101	7	2
96	Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. <i>Blood</i> , <b>2020</b> , 136, 2881-2892	2.2	196
95	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. <i>Haematologica</i> , <b>2020</b> , 105, 468-477	6.6	27

94	The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. <i>Leukemia</i> , <b>2020</b> , 34, 604-612	10.7	32
93	Evolution or revolution in multiple myeloma therapy and the role of the UK. <i>British Journal of Haematology</i> , <b>2020</b> , 191, 542-551	4.5	0
92	INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. <i>Future Oncology</i> , <b>2019</b> , 15, 1411-1428	3.6	10
91	Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1617-1628	2.2	12
90	The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 450-467	4.5	9
89	Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. <i>Haematologica</i> , <b>2019</b> , 104, 1440-1450	6.6	39
88	A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. <i>Lancet Haematology</i> , <b>2019</b> , 6, e154-e166	14.6	44
87	Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21 <b>2019</b> , 7, 164		17
86	Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , <b>2019</b> , 6, e616-e629	14.6	26
85	Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172). <i>Blood</i> , <b>2019</b> , 134, 3162-3162 <sup>2</sup>		
84	POEMS Syndrome and Disease Produced by Other Monoclonal Immunoglobulins <b>2019</b> , 615-619		
83	Subsequent Treatments, Responses and Survival in the Real World for Patients with Relapsed Multiple Myeloma Following Treatment with Lenalidomide. <i>Blood</i> , <b>2019</b> , 134, 4340-4340	2.2	
82	Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. <i>Haematologica</i> , <b>2019</b> , 104, 2358-2360	6.6	11
81	Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 999-1005	4.5	18
80	Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2019</b> , 20, 57-73	21.7	154
79	A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 121, 74-89	7	15
78	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , <b>2018</b> , 32, 1542-1560	10.7	40
77	The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma. <i>BMC Medical Research Methodology</i> , <b>2018</b> , 18, 66	4.7	14

76	The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. <i>Trials</i> , <b>2018</b> , 19, 169	2.8	4
75	Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival [Data from the Ukmrc Myeloma XI Trial. <i>Blood</i> , <b>2018</b> , 132, 122-122	2.2	3
74	Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone. <i>Blood</i> , <b>2018</b> , 132, 4482-4482	2.2	4
73	Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , <b>2018</b> , 132, 1996-1996	2.2	10
72	A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study. <i>Blood</i> , <b>2018</b> , 132, 302-302	2.2	5
71	Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial. <i>Blood</i> , <b>2018</b> , 132, 3274-3274	2.2	
70	Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials. <i>Blood</i> , <b>2018</b> , 132, 2000-2000	2.2	
69	Transplant Status Does Not Impact the Selection of Induction Regimens for Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Insight MM Prospective, Observational Study. <i>Blood</i> , <b>2018</b> , 132, 3289-3289	2.2	1
68	Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial. <i>Blood</i> , <b>2018</b> , 132, 3280-3280	2.2	
67	Daratumumab plus lenalidomide and dexamethasone lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. <i>Haematologica</i> , <b>2018</b> , 103, 2088-2096	6.6	133
66	Subclonal copy number is associated with prognosis in multiple myeloma. <i>Blood</i> , <b>2018</b> , 132, 2465-2469	2.2	21
65	RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature. <i>Blood</i> , <b>2018</b> , 132, 2154-2165	2.2	10
64	Myeloma: Patient accounts of their pathways to diagnosis. <i>PLoS ONE</i> , <b>2018</b> , 13, e0194788	3.7	11
63	Multiple myeloma: routes to diagnosis, clinical characteristics and survival - findings from a UK population-based study. <i>British Journal of Haematology</i> , <b>2017</b> , 177, 67-71	4.5	27
62	High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. <i>Haematologica</i> , <b>2017</b> , 102, 160-167	6.6	32
61	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , <b>2017</b> , 99, 199-206	3.8	15
60	Neutral tumor evolution in myeloma is associated with poor prognosis. <i>Blood</i> , <b>2017</b> , 130, 1639-1643	2.2	14
59	Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide. <i>Blood</i> , <b>2017</b> , 130, 904-904	2.2	10

58	Safety and efficacy of daratumumab-based regimens in elderly (≥5 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 8033-8033	2.2	3
57	Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1926-1937	4.7	11
56	The "Next Big Thing" in Treatment for Relapsed or Refractory Multiple Myeloma May Be Held Back by Design-Between the Lines. <i>JAMA Oncology</i> , <b>2016</b> , 2, 1405-1406	13.4	
55	Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1926-1937	4.7	7
54	Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux. <i>Blood</i> , <b>2016</b> , 128, 1151-1151	2.2	21
53	Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial. <i>Blood</i> , <b>2016</b> , 128, 245-245	2.2	8
52	Immune Biomarkers Identify Sustained Quantitative and Functional Immune Reconstitution in the Setting of Adjunctive Lenalidomide Following T-Depleted RIC-Allo SCT for Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 4585-4585	2.2	1
51	Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen. <i>Haematologica</i> , <b>2016</b> , 101, e69-71	6.6	33
50	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. <i>Drugs</i> , <b>2016</b> , 76, 853-67	12.1	26
49	The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , <b>2016</b> , 3, e340-51	14.6	78
48	APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. <i>Nature Communications</i> , <b>2015</b> , 6, 6997	17.4	176
47	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 2000-2051	4.7	114
46	A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma. <i>Genes Chromosomes and Cancer</i> , <b>2015</b> , 54, 91-8	5	26
45	Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. <i>Blood</i> , <b>2015</b> , 125, 1932-5	2.2	128
44	Optimizing the management of patients with spinal myeloma disease. <i>British Journal of Haematology</i> , <b>2015</b> , 171, 332-43	4.5	20
43	Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial. <i>British Journal of Haematology</i> , <b>2015</b> , 170, 336-48	4.5	13
42	Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy. <i>Cellular Immunology</i> , <b>2015</b> , 297, 1-9	4.4	13
41	Bortezomib (Velcade), Thalidomide, Dexamethasone and Panobinostat (VTD-P) Is a Safe, Well Tolerated and Efficacious Regimen for Patients with Relapsed Multiple Myeloma: Preliminary Results of the Muk-Six Trial. <i>Blood</i> , <b>2015</b> , 126, 1826-1826	2.2	2

40	Outcomes Following Salvage Autologous Stem Cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation Therapy Following Bortezomib-Containing Re-Induction for Relapsed Multiple Myeloma (MM) May be Dependent on Age and Symptomatic Status Initiation of Re-Induction: Results from the Myeloma X (Intensive) Trial. <i>Blood</i> , <b>2015</b> , 125, 1981-1981	2.2	
39	High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , <b>2014</b> , 15, 274-285	21.7	117
38	Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC). <i>Blood</i> , <b>2014</b> , 124, 4745-4745	2.2	1
37	Optimizing induction and pretransplant consolidation for myeloma: Results of Myeloma XI, a phase III trial comparing different IMiDs.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8537-8537	2.2	
36	Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM). <i>Blood Reviews</i> , <b>2013</b> , 27, 155-64	11.1	30
35	Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2540-7	2.2	313
34	Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 6030-8	12.9	116
33	Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) Trial. <i>British Journal of Haematology</i> , <b>2013</b> , 163, 541-3	4.5	4
32	Identifying An Optimally Effective But Tolerable Dose Of Bendamustine In Combination With Thalidomide and Dexamethasone In Patients With Relapsed Or Refractory Multiple Myeloma. <i>Blood</i> , <b>2013</b> , 122, 286-286	2.2	1
31	Treatment Patterns & Survival In Multiple Myeloma Patients Sequentially Exposed To Thalidomide, Bortezomib & Lenalidomide In a UK Single Centre. <i>Blood</i> , <b>2013</b> , 122, 5380-5380	2.2	4
30	Lenalidomide Combined With Cyclophosphamide and Dexamethasone Is Effective and Well Tolerated Induction Treatment For Newly Diagnosed Myeloma Patients Of All Ages. <i>Blood</i> , <b>2013</b> , 122, 540-540	2.2	1
29	A New Multinational Observational Study In Multiple Myeloma: Initial Report Of The PREAMBLE Study. <i>Blood</i> , <b>2013</b> , 122, 1964-1964	2.2	0
28	Unrelated Cord Blood Transplantation (UCBT) In Adults In The UK: Evolution, Experience and Outcomes. A Retrospective Analysis On Behalf Of The British Society of Blood and Marrow Transplantation (BSBMT) and Eurocord. <i>Blood</i> , <b>2013</b> , 122, 3394-3394	2.2	
27	Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. <i>Haematologica</i> , <b>2012</b> , 97, 442-50	6.6	121
26	The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. <i>Blood</i> , <b>2012</b> , 119, 7-15	2.2	270
25	Efficacy and side-effect profile of long-term bisphosphonate therapy in patients (pts) with multiple myeloma (MM): MRC myeloma IX study results.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8015-8015	2.2	1
24	Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. <i>PLoS ONE</i> , <b>2012</b> , 7, e35981	3.7	54
23	BEAM-Campath Allogeneic Stem Cell Transplantation for Aggressive Non-Hodgkin's Lymphomas. An Analysis of Outcomes From the BSBMT. <i>Blood</i> , <b>2012</b> , 120, 2039-2039	2.2	

22	Lenalidomide Redresses the Effector T Cell:Treg Cell Imbalance in Patients with Multiple Myeloma.. <i>Blood</i> , <b>2012</b> , 120, 2977-2977	2.2	
21	Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation</i> , <b>2011</b> , 17, 1638-45	4.7	48
20	Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 743-52	21.7	133
19	Effect of combined dexamethasone/lenalidomide therapy on NK cell-receptor levels in myeloma patients. <i>Blood</i> , <b>2011</b> , 118, 6465-6; author reply 6466-8	2.2	12
18	Re-transplantation after bortezomib-based therapy. <i>British Journal of Haematology</i> , <b>2011</b> , 153, 666-8	4.5	6
17	Guidelines for the diagnosis and management of multiple myeloma 2011. <i>British Journal of Haematology</i> , <b>2011</b> , 154, 32-75	4.5	224
16	Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. <i>Blood</i> , <b>2011</b> , 118, 1231-8	2.2	163
15	The Role of High Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT) In PATIENTS with POEMS SYNDROME: A Retrospective study of the MM Subcommittee of the Chronic Leukemia Working Party of the EBMT,. <i>Blood</i> , <b>2011</b> , 118, 4115-4115	2.2	1
14	MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease. <i>Blood</i> , <b>2011</b> , 118, 993-993	2.2	1
13	National, Retrospective, Multi-Centre Comparison of Alemtuzumab- Versus ATG-Based Conditioning Regimens in Hematopoietic Stem Cell Transplantation for Aplastic Anemia: A Study From the British Society for Blood and Marrow Transplantation (BSBMT) (CTCR 09-03). <i>Blood</i> , <b>2011</b> , 118, 52-52	2.2	
12	Allogeneic Stem Cell Transplantation Induces Long Term Survival in Patients with Advanced Chronic Myeloid Leukaemia:A Study of the British Society for Blood and Marrow Transplantation,. <i>Blood</i> , <b>2011</b> , 118, 4125-4125	2.2	
11	First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. <i>Lancet, The</i> , <b>2010</b> , 376, 1989-99	40	443
10	Optimising Bone Disease In Myeloma; Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints: Results of the MRC Myeloma IX Trial. <i>Blood</i> , <b>2010</b> , 116, 311-311	2.2	3
9	Thalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results. <i>Blood</i> , <b>2010</b> , 116, 623-623	2.2	11
8	Reduced Intensity Allogeneic Transplants Are Well Tolerated In Patients Over the Age of 60: Identification of Factors Predicting Overall Survival. <i>Blood</i> , <b>2010</b> , 116, 2361-2361	2.2	
7	Feasibility and Efficacy of Administration of Bortezomib-Containing Regimens to Patients Over the Age of 70 Years. <i>Blood</i> , <b>2010</b> , 116, 5035-5035	2.2	
6	Deletion 13, Detected by Metaphase Analysis, Is Not a Significant Prognostic Indicator In Myeloma. <i>Blood</i> , <b>2010</b> , 116, 2980-2980	2.2	
5	The Role of High Dose Chemotherapy and Autologous Stem Cell Transplantation In Patients with Multiple Myeloma Refractory to Initial Induction Therapy. <i>Blood</i> , <b>2010</b> , 116, 1341-1341	2.2	



4	CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. <i>British Journal of Haematology</i> , <b>2009</b> , 144, 686-95	4.5	116
3	Regulatory T-Cell Subsets Demonstrate Quantitative Differences but Not Functional Abnormalities in Patients with Multiple Myeloma (MM) Compared with Healthy Controls.. <i>Blood</i> , <b>2007</b> , 110, 3511-3511 <sup>2.2</sup>		
2	Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed by IL-15. <i>Journal of Immunology</i> , <b>2001</b> , 167, 553-61	5.3	68
1	Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. <i>Journal of Leukocyte Biology</i> , <b>1999</b> , 66, 981-8	6.5	82